Investigating the Effects of a High GI Versus a Low GI Diet on Hepatic Metabolism and Satiety Levels in Healthy Subjects
Launched by UNILEVER R&D · Jun 23, 2015
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
8 Healthy subject will be scanned the start and end of a 7 day high versus low glycaemic in diet with a 4 week washout between arms. During scan days the hepatic glycogen response to a corresponding high versus low glycaemic index test meal will be measured using 13C Magnetic resonance spectroscopy (MRS) to explore any acute changes in metabolic response. Baseline liver lipid levels will be measured using 1H MRS to explore any long term changes in liver lipid levels.
Blood samples will also be obtained throughout the test day to measure for blood glucose, insulin and blood hormone response...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male
- • Caucasian
- • Self-reported non-athletic but healthy: not carrying out strenuous exercise (no high sweat, out of breath, high heart rate activities and less than 2 hours moderate exercise a week), moderate drinkers (less than 3 units a day), no smokers
- • Routinely eating 3 meals a day
- • Stable weight
- • Age ≥ 18 and ≤ 35
- • Body mass index (BMI - weight / squared height ) ≥ 20.0 and ≤ 27.0 kg/m2
- • Suitable for MRI scanning (e.g., absence of metal implants, infusion pumps and pacemakers) as assessed by the attached MRI safety questionnaire.
- • Suitable for blood samples and cannula insertion (e.g., no aversion to needles)
- • Willing to follow both prescribed diet plans
- • Not taking any concurrent medication
- Exclusion Criteria:
- • No diabetics or other metabolic disorders (e.g. insulin resistance, thyroid dysfunction)
- • No volunteers with liver disease
- • No clotting disorders
- • No Participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study.
- • No use of any medically or self-prescribed diet from the moment of pre-study examination till the end of the study
- • Taking prescription medication or any other drugs that may influence liver function or glucose and energy metabolism.
- • Any allergy or food intolerance
- • Unsuitable for MR scanning (i.e. have pacemakers and/or medical implants)
- • The subject is an employee of Unilever or the site conducting the study.
About Unilever R&D
Unilever R&D is a leading global research and development organization dedicated to advancing science and innovation in consumer goods, particularly in the areas of personal care, home care, and food products. With a commitment to sustainability and health, Unilever R&D employs cutting-edge research methodologies and collaborates with academic institutions, industry partners, and regulatory bodies to drive product innovation and improve consumer well-being. Their clinical trials focus on evaluating the efficacy and safety of new formulations, ensuring that Unilever consistently delivers high-quality, scientifically validated products that meet the evolving needs of consumers worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, Nottinghamshire, United Kingdom
Patients applied
Trial Officials
Penny Gowland, PhD
Principal Investigator
School of Physics & Astronomy, University of Nottingham
Robin Spiller, MD
Principal Investigator
School of Medicine, University of Nottingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials